Outcome of Haploidentical versus Matched Sibling Donors in Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Investigators retrospectively analyzed adult patients with acute lymphoblastic leukemia who underwent their first allogeneic stem cell transplantation in first or second complete remission between 2012 and 2018, either from a T cell replete Haplo or matched sibling donor donor.
[Journal of Hematology & Oncology]
Nagler, A., Labopin, M., Houhou, M., Aljurf, M., Mousavi, A., Hamladji, R.-M., Al Zahrani, M., Bondarenko, S., Arat, M., Angelucci, E., Koc, Y., Gülbas, Z., Sica, S., Bourhis, J. H., Canaani, J., Brissot, E., Giebel, S., & Mohty, M. (2021). Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology & Oncology, 14(1), 53. https://doi.org/10.1186/s13045-021-01065-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia

Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38 fraction of the malignant clone.
[Leukemia]
Eisenwort, G., Sadovnik, I., Keller, A., Ivanov, D., Peter, B., Berger, D., Stefanzl, G., Bauer, K., Slavnitsch, K., Greiner, G., Gleixner, K. V., Sperr, W. R., Willmann, M., Sill, H., Bettelheim, P., Geissler, K., Deininger, M., Rülicke, T., & Valent, P. (2021). Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 1–12. https://doi.org/10.1038/s41375-021-01227-z Cite
Abstract
Bookmark

No account yet? Register

0
Share

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
[Bio-Path Holdings, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
[Kite (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Post-Transplant Food Anaphylaxis in an Adult Cord Blood Transplant Recipient (Ms. No. IJHM-D-20-01037R1)

Scientists describe a case of new-onset food anaphylaxis after cord blood transplantation (CBT) in an adult patient that demonstrated that post-CBT allergen-challenge was not a risk for long-term allergic sensitization, even in adult recipients.
[International Journal of Hematology]
Kawahara, A., Nakanishi, T., Goto, M., Akao, K., Katsuragi, T., & Tsukada, J. (2021). Post-transplant food anaphylaxis in an adult cord blood transplant recipient (Ms. No. IJHM-D-20-01037R1). International Journal of Hematology. https://doi.org/10.1007/s12185-021-03140-8 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

While acute myeloid leukemia represents an intuitive disease in which to investigate chimeric antigen receptor (CAR) based immunotherapies, key biological differences to B-cell malignancies have complicated progress to date.
[Cancers]
Gurney, M., & O’Dwyer, M. (2021). Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. Cancers, 13(7), 1568. https://doi.org/10.3390/cancers13071568 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase III Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Rafael Pharmaceuticals, Inc. announced that it has crossed the enrollment of 150 patients in its Phase III clinical trial for patients with relapsed or refractory AML.
[Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

HOXBLINC Long Non-Coding RNA Activation Promotes Leukemogenesis in NPM1-Mutant Acute Myeloid Leukemia

Scientists showed that the activation of HOXBLINC, a HOXB locus-associated long non-coding RNA, was a critical downstream mediator of NPM1c+-associated leukemic transcription program and leukemogenesis.
[Nature Communications]
Zhu, G., Luo, H., Feng, Y., Guryanova, O. A., Xu, J., Chen, S., Lai, Q., Sharma, A., Xu, B., Zhao, Z., Feng, R., Ni, H., Claxton, D., Guo, Y., Mesa, R. A., Qiu, Y., Yang, F.-C., Li, W., Nimer, S. D., … Xu, M. (2021). HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nature Communications, 12(1), 1956. https://doi.org/10.1038/s41467-021-22095-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

YBX1 Is Required for Maintaining Myeloid Leukemia Cell Survival by Regulating BCL2 Stability in an m6A-Dependent Manner

Investigators showed that YBX1 was specifically required for maintaining myeloid leukemia cell survival in an m6A-dependent manner.
[Blood]
Feng, M., Xie, X., Han, G., Zhang, T., Li, Y., Li, Y., Yin, R., Wang, Q., Zhang, T., Wang, P., Hu, J., Cheng, Y., Gao, Z., Wang, J., Chang, J., Cui, M., Gao, K., Chai, J., Liu, W., … Zhang, H. (2021). YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood, blood.2020009676. https://doi.org/10.1182/blood.2020009676 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Promyelocytic Leukemia Protein (PML) Promotes the Phenotypic Switch of Smooth Muscle Cells in Atherosclerotic Plaques of Human Coronary Arteries

To identify possible functional consequences of PML-accumulation, differentiated human coronary artery smooth muscle cells were transfected with a vector containing the intact PML-gene.
[Clinical Science]
Karle, W., Becker, S., Stenzel, P., Knosalla, C., Siegel, G., Baum, O., Zakrzewicz, A., & Berkholz, J. (2021). Promyelocytic leukemia protein (PML) promotes the phenotypic switch of smooth muscle cells in atherosclerotic plaques of human coronary arteries. Clinical Science, CS20201399. https://doi.org/10.1042/CS20201399 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Trispecific CD19-CD20-CD22–Targeting duoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models

Researchers engineered trispecific duoCAR-T cells with lentiviral vectors encoding two CAR open reading frames that target CD19, CD20, and CD22.
[Science Translational Medicine]
Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L., Steimle, B., Mahmud, H., Anthony-Gonda, K., Krueger, W., Zhu, Z., Dimitrov, D. S., Orentas, R. J., & Dropulić, B. (2021). Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 13(586). https://doi.org/10.1126/scitranslmed.abc6401 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share